AZD8076
mAbexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 19, 2022 (NCT05293249)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05293249 | Phase 1 | May 19, 2022 | AstraZeneca, Inovio Pharmaceuticals, The Wistar Institute, University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 0 | 1 | 2022 |
| Inovio Pharmaceuticals | For profit | 1 | 0 | 1 | 2022 |
| The Wistar Institute | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1